Table 4.
Compound | KM (μM) | Vmax (μmol/mg/min) |
kcat (S−1) | kcat/KM/104 (S−1M−1) |
MIC against bacterium with APH(3′)-IIIa a |
MIC ratio b |
---|---|---|---|---|---|---|
Kanamycin A | 8.2±0.7 | 6.96±0.12 | 3.48±0.06 | 42.4 | 125 (Kan B) | 32 (Kan B) |
Amikacin | 57.4±5.7 | 2.75±0.13 | 1.38±0.07 | 24.0 | 1 | 1 |
Neomycin B | 6.0±0.8 | 3.22±0.17 | 1.61±0.09 | 26.8 | 64 | 8 |
4a | 160±15 | 0.41±0.03 | 0.21±0.02 | 0.13 | 125 | 8 |
4b | 127±13 | 0.75±0.04 | 0.38±0.02 | 0.30 | 32-64 | 4 |
4c | 120±14 | 0.65±0.05 | 0.33±0.03 | 0.28 | 64-125 | 8 |
4d | 410±38 | 0.30±0.03 | 0.15±0.02 | 0.037 | 16-32 | 2 |
4e | 100±9 | 0.72±0.07 | 0.36±0.04 | 0.36 | 125 | 8 |
4f | 150±16 | 0.54±0.05 | 0.27±0.03 | 0.18 | 125 | 8 |
4g | 111±12 | 0.68±0.04 | 0.34±0.02 | 0.3 | 64 | 4 |
4h | 171±18 | 0.41±0.04 | 0.21±0.02 | 0.12 | 64-125 | 8 |
4i | 175±18 | 0.40±0.04 | 0.20±0.02 | 0.14 | 64-125 | 8 |
5a | 48±6 | 0.95±0.06 | 0.48±0.05 | 1.0 | 64 | 8 |
5b | 58±4 | 0.85±0.08 | 0.42±0.05 | 0.72 | 1-2 | 0.5 |
5c | 60±7 | 0.84±0.05 | 0.42±0.03 | 0.7 | 2 | 1-2 |
5d | 400±35 | 0.38±0.04 | 0.19±0.02 | 0.048 | 32-64 | 4 |
5e | 50±4 | 0.93±0.07 | 0.47±0.05 | 0.94 | 125 | 8 |
5f | 75±8 | 0.88±0.06 | 0.44±0.03 | 0.6 | 32 | 2 |
5g | 60±5 | 0.90±0.09 | 0.45±0.05 | 0.75 | 64 | 4 |
5h | 80±9 | 0.63±0.07 | 0.32±0.03 | 0.4 | 64 | 4 |
5i | 322±31 | 0.57±0.06 | 0.29±0.03 | 0.1 | 64 | 4 |
5j | 42±4 | 1.01±0.09 | 0.51±0.05 | 1.2 | 32-64 | 4 |
5k | 78±8 | 0.79±0.08 | 0.40±0.03 | 0.51 | 32-64 | 4 |
5l | 53±6 | 0.86±0.09 | 0.43±0.04 | 0.81 | 250 | 8 |
5m | 63±7 | 0.82±0.09 | 0.41±0.04 | 0.65 | 64-125 | 8 |
5n | 57±6 | 0.93±0.10 | 0.47±0.05 | 0.82 | 64 | 4 |
5o | 70±8 | 0.72±0.07 | 0.36±0.04 | 0.51 | 64 | 8 |
5p | 75±8 | 0.70±0.07 | 0.35±0.04 | 0.47 | 64-125 | 8 |
33 | >500 | <0.1 | <0.05 | <0.01 | 64-125 | 8 |
Unit: μg/mL,
MIC ratio = (MIC against E. coli (TG1))/(MIC against E. coli (TG1) with APH(3′)-IIIa )